{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:43:41Z","timestamp":1788921821376,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["51340"],"award-info":[{"award-number":["51340"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["48279"],"award-info":[{"award-number":["48279"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejmech.2026.118985","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T17:58:48Z","timestamp":1779299928000},"page":"118985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of new quinazolin-4-ones as dual EGFR\/c-SRC inhibitors with potential to overcome bypass-mediated resistance in cancer"],"prefix":"10.1016","volume":"315","author":[{"given":"Mohamed A.","family":"Radwan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragaa Y.","family":"El-Mahdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7527-1655","authenticated-orcid":false,"given":"Reem K.","family":"Arafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejmech.2026.118985_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118985_bib2","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118985_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Shyam Sunder","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118985_bib4","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/molecules27030819","article-title":"Structural insight and development of EGFR tyrosine kinase inhibitors","volume":"27","author":"Amelia","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118985_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1258371","article-title":"EGFR trafficking: effect of dimerization, dynamics, and mutation","volume":"13","author":"Schultz","year":"2023","journal-title":"Front. Oncol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.118985_bib6","article-title":"Phosphoproteomic analysis identified mutual phosphorylation of FAK and src as a mechanism of osimertinib resistance in EGFR-mutant lung cancer","volume":"5","author":"Tozuka","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"issue":"45","key":"10.1016\/j.ejmech.2026.118985_bib7","doi-asserted-by":"crossref","first-page":"4917","DOI":"10.1038\/s41388-022-02487-4","article-title":"Src: coordinating metabolism in cancer","volume":"41","author":"Pelaz","year":"2022","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ejmech.2026.118985_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3892\/ol.2023.14116","article-title":"Increased c-SRC expression is involved in acquired resistance to lenvatinib in hepatocellular carcinoma","volume":"26","author":"Takahashi","year":"2023","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2026.118985_bib9","doi-asserted-by":"crossref","first-page":"8983","DOI":"10.1038\/s41598-022-12995-8","article-title":"AXL\/CDCP1\/SRC axis confers acquired resistance to osimertinib in lung cancer","volume":"12","author":"Murakami","year":"2022","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118985_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0117215","article-title":"Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting","volume":"10","author":"Rao","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.118985_bib11","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ejmech.2012.06.055","article-title":"Novel oxazolo[4,5-g]quinazolin-2(1H)-ones: dual inhibitors of EGFR and src protein tyrosine kinases","volume":"55","author":"Lin","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib12","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ejmech.2017.05.006","article-title":"Design, synthesis and evaluation of azaacridine derivatives as dual-target EGFR and src kinase inhibitors for antitumor treatment","volume":"136","author":"Cui","year":"2017","journal-title":"Eur. J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.118985_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.bmc.2015.12.011","article-title":"Design, synthesis and evaluation of acridine derivatives as multi-target src and MEK kinase inhibitors for anti-tumor treatment","volume":"24","author":"Cui","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112640","article-title":"Novel quinazoline-based EGFR kinase inhibitors: a review focussing on SAR and molecular docking studies (2015-2019)","volume":"204","author":"Bhatia","year":"2020","journal-title":"Eur. J. Med. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2026.118985_bib15","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3390\/molecules28030978","article-title":"Quinazolinones, the winning horse in drug discovery","volume":"28","author":"Alsibaee","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118985_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108753","article-title":"Development of novel quinazolinone-based compounds with anti-proliferative activity as dual STAT-3 and c-Src inhibitors: design, synthesis and molecular dynamic studies","volume":"163","author":"Abdelall","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2024.109640","article-title":"Structure-based design of new anticancer N3-Substituted quinazolin-4-ones as type I ATP-Competitive inhibitors targeting the deep hydrophobic pocket of EGFR","volume":"186","author":"El-Mahdy","year":"2025","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.118985_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113609","article-title":"Design, synthesis and evaluation of new quinazolin-4-one derivatives as apoptotic enhancers and autophagy inhibitors with potent antitumor activity","volume":"222","author":"ElZahabi","year":"2021","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118985_bib19","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3109\/14756366.2016.1158714","article-title":"Synthesis, molecular modeling and NAD(P)H:quinone oxidoreductase 1 inducer activity of novel 2-phenylquinazolin-4-amine derivatives","volume":"31","author":"Ghorab","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111693","article-title":"New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: design, synthesis, cytotoxicity evaluation and in silico studies","volume":"183","author":"El-Sayed","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib21","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2026.118985_bib22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejmech.2016.09.039","article-title":"Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2","volume":"125","author":"Zhang","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118985_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108185","article-title":"Identification of a novel src inhibitor K882 derived from quinazoline-based stilbenes with anti-NSCLC effect","volume":"156","author":"Ma","year":"2025","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.ejmech.2026.118985_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/abbs\/gmt042","article-title":"c-Src regulates cell cycle proteins expression through protein kinase B\/glycogen synthase kinase 3 beta and extracellular signal-regulated kinases 1\/2 pathways in MCF-7 cells","volume":"45","author":"Liu","year":"2013","journal-title":"Acta Biochim. Biophys. Sin."},{"issue":"5","key":"10.1016\/j.ejmech.2026.118985_bib25","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3390\/cancers9050052","article-title":"Epidermal growth factor receptor cell proliferation signaling pathways","volume":"9","author":"Wee","year":"2017","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.ejmech.2026.118985_bib26","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1042\/BJ20050465","article-title":"STAT3-mediated transcription of Bcl-2, Mcl-1 and c-IAP2 prevents apoptosis in polyamine-depleted cells","volume":"392","author":"Bhattacharya","year":"2005","journal-title":"Biochem. J."},{"issue":"9","key":"10.1016\/j.ejmech.2026.118985_bib27","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1038\/sj.emboj.7601085","article-title":"Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression","volume":"25","author":"Cursi","year":"2006","journal-title":"EMBO J."},{"issue":"13","key":"10.1016\/j.ejmech.2026.118985_bib28","doi-asserted-by":"crossref","first-page":"3915","DOI":"10.1021\/jm9002928","article-title":"Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc","volume":"52","author":"Getlik","year":"2009","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2026.118985_bib29","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jhet.1869","article-title":"Reactivity of 2-Methyl-4 H -3,1-benzoxazin-4-ones and 2-Methyl-4 H -pyrido[2,3- d ][1,3]oxazin-4-one under microwave irradiation conditions: reactivity of oxazinones under microwave irradiation","volume":"50","author":"Prousis","year":"2013","journal-title":"J. Heterocycl. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2026.118985_bib30","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.3390\/ph16081120","article-title":"Design and synthesis of new anthranyl phenylhydrazides: antileishmanial activity and structure\u2013activity relationship","volume":"16","author":"Do Carmo Maquiaveli","year":"2023","journal-title":"Pharmaceuticals"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004307?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426004307?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T17:13:20Z","timestamp":1783185200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426004307"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":30,"alternative-id":["S0223523426004307"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118985","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of new quinazolin-4-ones as dual EGFR\/c-SRC inhibitors with potential to overcome bypass-mediated resistance in cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118985","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118985"}}